Olmesartan Medoxomil/Amlodipin Ascend (Olmesartan Medoxomil, Amlodipine)

Olmesartan Medoxil/Amlodipine is used in cardiovascular therapy targeting the renin‑angiotensin system and calcium‑channel pathways.

• Hypertension: Provides effective blood pressure reduction when monotherapy is insufficient.
• Chronic heart failure: Improves symptoms and may reduce hospitalisation risk in patients with reduced ejection fraction.
• Diabetic nephropathy: Slows progression of kidney damage associated with type 2 diabetes.

• Olmesartan medoxil blocks the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction and aldosterone release. Amlodipine, a dihydropyridine calcium‑channel blocker, inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation and further lowering of blood pressure. The combined effect produces additive antihypertensive activity.

Adverse reactions may occur with any antihypertensive regimen and should be monitored.

Common Side Effects

• Dizziness or light‑headedness
• Peripheral edema
• Headache
• Flushing
• Fatigue
• Nasal congestion

Serious or Rare Side Effects

• Angio‑edema
• Severe hypotension
• Hepatic enzyme elevation
• Jaundice
• Acute kidney injury
• Myocardial infarction in susceptible patients

When prescribing Olmesartan Medoxil/Amlodipine, clinicians should consider several safety aspects.

• Monitor blood pressure: Adjust dose if target is not reached.
• Assess renal function: Use caution in patients with impaired kidneys.
• Check electrolytes: Watch for potassium abnormalities.
• Evaluate hepatic status: Use with care in liver disease.
• Review concomitant medications: Avoid drugs that may cause additive hypotension.
• Store at ambient temperature: Keep below 25°C in the original packaging, protected from moisture.

Olmesartan Medoxil/Amlodipine may interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid)

• Potassium‑rich supplements or salts: Increases risk of hyper‑kalemia.
• Aliskiren combined with ACE‑inhibitors or ARBs in diabetic patients: Heightened risk of renal impairment.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): May raise amlodipine levels.

Moderate Interaction 

• Non‑steroidal anti‑inflamatory 

g     \  ");